vs
Side-by-side financial comparison of SolarMax Technology, Inc. (SMXT) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $46.6M, roughly 1.5× SolarMax Technology, Inc.). SolarMax Technology, Inc. runs the higher net margin — -1.9% vs -49.0%, a 47.2% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 623.5%).
SolarMax Technology, Inc. develops, manufactures and sells high-efficiency solar PV modules and clean energy systems. It serves residential, commercial and industrial clients in North America and key Asia-Pacific markets, offering installation and after-sales support to boost low-carbon energy use.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SMXT vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.6M | $70.6M |
| Net Profit | $-872.2K | $-34.6M |
| Gross Margin | 2.7% | — |
| Operating Margin | -2.7% | -56.7% |
| Net Margin | -1.9% | -49.0% |
| Revenue YoY | 623.5% | 81958.1% |
| Net Profit YoY | 77.7% | 54.9% |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $46.6M | — | ||
| Q3 25 | $30.6M | $70.6M | ||
| Q2 25 | $6.9M | — | ||
| Q1 25 | $6.9M | — | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $6.3M | — |
| Q4 25 | $-872.2K | — | ||
| Q3 25 | $-2.3M | $-34.6M | ||
| Q2 25 | $-1.9M | — | ||
| Q1 25 | $-1.3M | — | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $-9.6M | — |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 20.5% | — | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 19.9% | — |
| Q4 25 | -2.7% | — | ||
| Q3 25 | -6.9% | -56.7% | ||
| Q2 25 | -25.7% | — | ||
| Q1 25 | -16.7% | — | ||
| Q4 24 | -27.9% | — | ||
| Q3 24 | -158.4% | — |
| Q4 25 | -1.9% | — | ||
| Q3 25 | -7.4% | -49.0% | ||
| Q2 25 | -27.6% | — | ||
| Q1 25 | -18.7% | — | ||
| Q4 24 | -60.6% | — | ||
| Q3 24 | -152.0% | — |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.03 | — | ||
| Q4 24 | $-0.07 | — | ||
| Q3 24 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.0M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-12.2M | $503.0M |
| Total Assets | $91.3M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.0M | — | ||
| Q3 25 | $5.7M | $490.9M | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $6.8M | — | ||
| Q4 24 | $7.1M | — | ||
| Q3 24 | $8.6M | — |
| Q4 25 | $-12.2M | — | ||
| Q3 25 | $-11.8M | $503.0M | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $-15.9M | — | ||
| Q4 24 | $-15.1M | — | ||
| Q3 24 | $-10.9M | — |
| Q4 25 | $91.3M | — | ||
| Q3 25 | $58.7M | $577.1M | ||
| Q2 25 | $38.2M | — | ||
| Q1 25 | $38.6M | — | ||
| Q4 24 | $38.6M | — | ||
| Q3 24 | $43.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.5M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $3.4M | $-84.6M | ||
| Q2 25 | $220.7K | — | ||
| Q1 25 | $-601.1K | — | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $203.6K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SMXT
| Yabucoa | $35.9M | 77% |
| Other | $10.7M | 23% |
VRDN
Segment breakdown not available.
